Source: FinanzNachrichten

Auromedics: AuroMedics Pharma Recalls Certain Polymyxin B For Injection

WASHINGTON (dpa-AFX) - AuroMedics Pharma LLC is recalling certain Polymyxin B for Injection USP, 500,000 Units/Vial to the consumer level in the United States citing the possible presence of parti...

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
25-100
Ronald F Quadrel's photo - CEO of Auromedics

CEO

Ronald F Quadrel

CEO Approval Rating

73/100

Read more